At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 355 enrolled
Drug / intervention
SB206 12% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
In Brief
A Phase 3 clinical trial evaluating SB206 12% and Placebo for Molluscum Contagiosum. Completed, enrolled 355 participants across 27 sites.
Detailed Summary
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMolluscum Contagiosum
CountriesUnited States
CollaboratorsSynteract, Inc.
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJun 2019
Primary CompletionNov 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 25, 2019
Enrollment StartJun 13, 2019
Primary CompletionNov 11, 2019
Study CompletionFeb 3, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.2 years ago
Interventions
SB206 12%drug
Topically once daily
Placebodrug
Topically once daily